Unique ID issued by UMIN | UMIN000003755 |
---|---|
Receipt number | R000004549 |
Scientific Title | A Phase II study of Pemetrexed plus Carboplatin followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer. |
Date of disclosure of the study information | 2010/06/15 |
Last modified on | 2012/12/15 01:19:19 |
A Phase II study of Pemetrexed plus Carboplatin followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.
A Phase II study of Pemetrexed plus Carboplatin followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.
A Phase II study of Pemetrexed plus Carboplatin followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.
A Phase II study of Pemetrexed plus Carboplatin followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.
Japan |
Non-squamous non-small cell lung cancer
Pneumology | Chest surgery |
Malignancy
NO
To investigate the efficacy and safety of Pemetrexed plus Carboplatin followed by maintenance Pemetrexed in patients with previously untreated stage III/IV or post-operative recurrent non-squamous non-small-cell and lung cancer.
Safety,Efficacy
Exploratory
Pragmatic
Phase II
One year survival
Evaluation of safety,
Objective response rate,
Progression Free Survival
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Four cycles of Pemetrexed + Carboplatin followed by maintenance Pemetrexed until disease progression
20 | years-old | <= |
Not applicable |
Male and Female
1) Histologically or cytologically confirmed non-sqamous non-small-cell lung cancer with Chemo-naive patients (Radiothrapy to any place other than primary and evaluable lesion is competent)
2) Patients who have measurable lesion (In 10mm Slice CT more than 20mm, in 5mm Slice CT more than 10mm) or evaluable lesion by RECIST
3) Stage III/IV without indication for curative resection and irradiation or post-operative recurrent disease without adjuvant chemotherapy or with at least one year interval from the last dosage of adjuvant chemotherapy
4) Patients aged 20 years or older
5) Karnofsky performance status 70-100
6) Adequate organ function, evaluated within 14 days before enrollment as;
WBC >= 4,000/mm3
Neu >= 2,000/mm3
Plt >= 100,000/mm3
Hb >= 9.5 g/dL
AST/ALT <= x 3 upper limit of normal range
T. Bil <= 1.5 g/dL
Ccr >= 60mL/min or sCr <= 1.2mg/dL
SpO2 >= 93% as room air
7) Excepted to live over 3 months after administration day
8) Written informed consent from the patients
Patients with at least one of the following conditions are ineligible
1) squamous cell carcinoma
2) Interstitial pneumonia or pulmonary fibrosis detectable on Chest X-ray
3) Pleural effusion, pericardial effusion and ascites to need treatment
4) Patients unable to take or unsupplied with folic acid and vitamin B12
5) Severe renal function disorder
6) SVC syndrome
7) Brain metastases with neurological symptoms
8) Active double cancer
9) Uncontrollable diabetes mellitus and hypertenson
10) Liver cirrhosis by image findings or laboratory examinations
11) History of severe heart disease (myocardial infarction within 6 months, unstable angina, post-PTCA or CAGB, signs of congestive heart failue, arrythmia with past history of heart failure, etc.)
12) Pregnancy, breast feeding and suspected pregnancy
13) History of grave drug allergic reaction
14) Acute inflammatory disease
15) An agreement is not obtained for support therapy such as transfusion etc
16) Having the bleeding tendency which is clinically apparent
17) Patients whose participation in the trial is judged to be inappropriate by the attendeing doctor
40
1st name | |
Middle name | |
Last name | Takashi Kijima |
Osaka University Hospital
Dept. of Respiratory Medicine
2-2 Yamada-oka, Suita 565-0871, Osaka, Japan
06-6879-3833
1st name | |
Middle name | |
Last name | Takashi Kijima |
Osaka University Hospital
Dept. of Respiratory Medicine
2-2 Yamada-oka, Suita 565-0871, Osaka, Japan
06-6879-3833
tkijima@imed3.med.osaka-u.ac.jp
Dept. of Respiratory Medicine,
Osaka University Hospital
Dept. of Respiratory Medicine,
Osaka University Hospital
Self funding
OULCSG
NO
2010 | Year | 06 | Month | 15 | Day |
Unpublished
Completed
2009 | Year | 12 | Month | 01 | Day |
2010 | Year | 01 | Month | 01 | Day |
2012 | Year | 11 | Month | 30 | Day |
2012 | Year | 11 | Month | 30 | Day |
2012 | Year | 11 | Month | 30 | Day |
2012 | Year | 11 | Month | 30 | Day |
2010 | Year | 06 | Month | 14 | Day |
2012 | Year | 12 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000004549